

10/509604#3

DT04 Rec'd PCT/PTO 27 SEP 2004

Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter Haynes Hutson

Int'l Appln.  
No. : PCT/GB03/01237Int'l Date  
Filed : 21 March 2003 (21/03/2003)

Serial No. : (To be assigned) Case No.: T1571P

Filed : September 27, 2004

For : USE OF A BENZOFURAN DERIVATIVE FOR THE  
TREATMENT OF ATTENTION DEFICIT  
HYPERACTIVITY DISORDERCommissioner for Patents  
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT Sept 27 2004  
POSTAL MAIL NO. 22 989588077 US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Louise Harris  
DATE Sept 27 2004

10/509604

DT04 Rec'd PCT/PTO 27 SEP 2004

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



Eric Thies  
Reg. No. 35,382  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904

Date: September 27, 2004

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	
Sheet	1	of	2	Docket No. T1571P Rec'd PCT/PTO 27 SEP 2004 107509604	

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

September 27, 2004

Peter Haynes Hutson

T1571P

Sheet

2

of

2

### NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*

Cite  
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Tarazi F. I. et al: "Dopamine D4 receptors: significance for molecular psychiatry at the millennium." MOLECULAR PSYCHIATRY. ENGLAND NOV. 1999, vol. 4, no. 6, pages 529-538

Licinio J: "The dopamine D4 receptor and attention deficit hyperactivity disorder." MOLECULAR PSYCHIATRY, ENGLAND MAY 1996, vol. 1, no. 2, May 1996, pages 83-84

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003